Opus Point Partners Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Opus Point Partners Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$217K	Hold	5,064	–	–	0.39%	53
2019 Q2	$322K	Hold	5,064	–	–	0.48%	50
2019 Q1	$351K	Sell	5,064 -275	-5%	-$15.7K	0.48%	50
2018 Q4	$232K	Sell	5,339 -795	-13%	-$43.5K	0.51%	34
2018 Q3	$468K	Sell	6,134 -177	-3%	-$14.4K	1.12%	26
2018 Q2	$485K	Sell	6,311 -980	-13%	-$63.3K	1.05%	27
2018 Q1	$372K	Sell	7,291 -1,181	-14%	-$59.5K	0.73%	32
2017 Q4	$393K	Sell	8,472 -3,427	-29%	-$168K	0.34%	42
2017 Q3	$634K	Buy	11,899 +5,742	+93%	+$340K	0.57%	41
2017 Q2	$382K	Sell	6,157 -6,044	-50%	-$364K	0.35%	51
2017 Q1	$827K	Buy	12,201 +1,337	+12%	+$102K	0.61%	38
2016 Q4	$764K	Buy	10,864 +3,790	+54%	+$269K	0.61%	36
2016 Q3	$502K	Hold	7,074	–	–	0.28%	38
2016 Q2	$346K	Sell	7,074 -6,426	-48%	-$416K	0.33%	36
2016 Q1	$855K	Buy	+13,500	New	+$883K	0.66%	34
2015 Q3	–	Sell	-9,000	Closed	-$922K	–	58
2015 Q2	$922K	Sell	9,000 -3,000	-25%	-$233K	0.73%	35
2015 Q1	$745K	Buy	+12,000	New	+$667K	0.62%	43

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Opus Point Partners Management's RARE Position: Q3 2019 in Review

Opus Point Partners Management held its Ultragenyx Pharmaceutical (RARE) position steady in Q3 2019 at 5,064 shares worth $217K. The position accounts for 0.39% of the portfolio, ranked #53.

Opus Point Partners Management first reported a position in RARE in Q1 2015 and has held it in 17 quarters since. The position peaked at $922K in Q2 2015. 173 funds tracked by Wall St. Rank hold RARE as of Q3 2019.

Opus Point Partners Management held 5,064 shares of Ultragenyx Pharmaceutical worth $217K as of Q3 2019.
Opus Point Partners Management left its Ultragenyx Pharmaceutical share count unchanged in Q3 2019.
Ultragenyx Pharmaceutical made up 0.39% of Opus Point Partners Management's portfolio in Q3 2019, its #53 holding.
Opus Point Partners Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 17 quarters since.
Opus Point Partners Management's Ultragenyx Pharmaceutical position peaked at $922K in Q2 2015.
173 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.